
price close busi octob
medic devic heart valv therapi includ
tissu valv mechan valv repair product
biomed devic servic
growth leverag beauti thing reiter
buy target
earn leverag continu least firm preemin
tavr franchis deliv auspici result heel recent low-
risk approv wit ew tavr sale grew y/i underli basi eclips
our/consensu revenu estim tune deliv kind
earn leverag preview see note expect
next quarter well lr approv clearli catalyz tavr market drive us
procedur volum growth
check suggest tavr trend continu portend upsid firm
near- long-term tavr market outlook manag reiter see ww
tavr market reach inde think ew could revisit increas
long-term tavr market project upcom analyst day decemb given
upsid potenti see ew tavr franchis coupl tremend
oper leverag tavr sale portend model reiter buy rate
ew look beyond bullish outlook firm remain predic
signific size under-penetr thu futur growth potenti ew target
tam tavr tmtt think ew possess elit innov prowess remain
commit expand leadership posit structur heart market beyond
think ew posit deliv top- bottom-lin growth large-
cap peer group least next year reiter buy target
tavr busi highlight ew tavr busi impli underli tavr
market dynam acceler significantli ew global tavr sale
y/i underli basi notabl strength us market term
tavr market heel low-risk approv ew estim total us tavr
procedur increas y/i quarter ew experienc growth line
overal market manag note bolu patient sidelin sinc
low-risk present past march contribut quarterli procedur
strength check suggest pipelin untreat sever symptomat
patient remain robust ou y/i tavr growth north ew grow
line market base recent strong trend ew increas tavr
guidanc firm expect full-year underli growth nearli vs
previous firm continu model tavr ww market
think base recent trend outlook could ultim prove conserv
view potenti manag revisit long-term project earli
upcom analyst day decemb
tmtt busi updat evolv outlook ew record tmtt sale
sequenti step total revenu pascal heel
ce mark approv continu fuel busi although manag note
price disciplin limit sale upsid quarter continu pg
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
tmtt busi updat evolv outlook continu base recent
trend manag anticip total tmtt sale fall
previous forecast guidanc total tmtt sale
expect doubl total revenu clinic pipelin side
busi ew updat line prior expect firm
remain track regard mileston pascal us
firm continu enrol clasp iid us ew recent commenc
enrol clasp iif replac ef work ew
platform evoqu continu progress ew still plan
commenc us pivot late final tricuspid firm
continu move forward pascal cardioband program
enrol firm clasp ii tr pivot set begin activ site calendar
outlook posit updat top-lin guidanc given firm strong
perform manag provid posit updat sale
expect anticip total sale top end current guidanc
rang busi segment compani expect tavr
thvt sale top end guidanc rang impli underli
sale growth nearli firm maintain total surgic heart revenu
guidanc rang critic manag
anticip total busi segment sale high end guidanc rang
casm contribut sale expect
fairli minim impact total sale manag lower tmtt
revenu expect anticip sale fall prior guidanc
pascal europ repres primari contributor sale
figur edward result vs cg estim consensu project
buy unchang target price octob
biomed devic servic
deriv price target appli price-to-earnings
pro forma ep estim repres premium
buy unchang target price octob
biomed devic servic
p/e/g valuat financi metric use current median large-cap medic devic price-to-earnings multipl med-tech comp group ep compound-annual-growth-rate forward large-cap medic devic p/e/growth multipl forma ep growth p/e/g multipl price-to-earnings multipl forma mo lifesci averag implant center total unit total ew ww tavi revenu ex growth averag total unit total ww tavi revenu growth averag total unit total ww tavi revenu growth player ww tavi revenu ww implant patient popul player tavi ww revenu market figur tavi us market share
buy unchang target price octob
biomed devic servic
edward lifesci implant averag implant total unit asp ew us revenu averag total unit asp total us revenu averag total unit asp us revenu player us revenu us implant address patient penetr us tavr market figur tavi eu/row market share
buy unchang target price octob
biomed devic servic
detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact inform appear front page report
buy unchang target price octob
biomed devic servic
million except per share revenu gross oper expens incom pre-tax incom tax interest exp eitf add-back net incom share ep forma ex ia margin analysi gross margin pro sale sale y/i revenu growth growth growth incom pro forma incom forma ex-one-tim ia figur revenu model
buy unchang target price octob
biomed devic servic
buy unchang target price octob
biomed devic servic
